FDA Approves Zolbetuximab-clzb with Chemotherapy for Gastric or Gastro-Oesophageal Junction Adenocarcinoma By Ogkologos - November 13, 2024 497 0 Facebook Twitter Google+ Pinterest WhatsApp FDA also approved the VENTANA CLDN18 (43-14A) RxDx Assay as a companion diagnostic device Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR A Combination of Trastuzumab with Gemcitabine and Cisplatin Shows Promising Activity... November 24, 2023 Deputy Spends His Days Off Teaching Life Skills To Young Boys... December 26, 2021 EMA Recommends Extension of Therapeutic Indications for Polatuzumab Vedotin April 14, 2022 FDA Approves Pralsetinib for Non-Small Cell Lung Cancer with RET Gene... September 1, 2023 Load more HOT NEWS Majority of Patients With Cancer Are Willing To Be Vaccinated Against... Intratumoural and Intracavitary Administration of Ipilimumab Plus Nivolumab Is Feasible and... Man With Cancer Receives $15,000 Check From ‘Secret Santa’ To Help... Efficacy and Safety of Patritumab Deruxtecan in Patients with EGFR-mutated NSCLC...
